Alexander Chamessian
Assistant Professor University of Washington
Seminars
Monday 26th October 2026
Toward Degrader Analgesics: Leveraging Targeted Protein Degradation for Effective, Durable & Non-Addictive Pain Control
12:15 pm
- Overview of key preclinical proof-of-concept studies demonstrating the amenability of voltage-gated sodium channels (NaV1.7, NaV1.8, NaV1.9) to targeted protein degradation modalities (PROTACs and molecular glues)
- Discussion of differentiating advantages of degrader analgesics over occupancy-based pharmacology
- Discussion of the challenges and opportunities for bringing degrader analgesics to the clinic
